FIELD: biotechnology.
SUBSTANCE: invention relates to a conjugate which specifically binds an extracellular domain epitope PLVAP, and can be used in medicine.
EFFECT: obtained conjugate can be used to create a drug for effective therapy of hepatocellular carcinoma (HHC) with PLVAP-positive vascular system.
22 cl, 2 tbl, 1 ex, 24 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ANTI-B7-H4 ANTIBODY AND DRUG CONJUGATE AND MEDICAL USE THEREOF | 2020 |
|
RU2827531C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| ANTIBODY AND DRUG CONJUGATES FOR DESTRUCTION OF HEMATOPOIETIC STEM CELLS | 2017 |
|
RU2781444C2 |
| CONJUGATE OF ANTI-CEA ANTIBODY AND EXCATECAN ANALOGUE AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2833323C1 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| DRUG CONJUGATES CONTAINING ANTI-CLAUDIN 18.2 ANTIBODIES | 2016 |
|
RU2841168C2 |
| CD37-BINDING MOLECULES AND THEIR IMMUNOCONJUGATES | 2011 |
|
RU2742743C2 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
